Sandoz (SDZNY), Friday said that it has launched a generic formulation of paclitaxel in the US, the first generic to its reference medicine Abraxane, a nanoparticle formulation of paclitaxel, to be approved by the US Food and Drug Administration (FDA).
Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer.
The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on October 8, 2024.
Abraxane is sold by Abraxis BioScience, a Bristol-Myers Squibb company.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.